One of the world's leading mutual funds has taken advantage of its Silicon Valley location to become a meaningful VC player. Over the last five years, the firm invested nearly $1bn in late-stage and mid-stage venture capital deals.
As some venture capital firms and individual VCs dip their toes into the SPAC-sponsorship waters, LPs are figuring out how to deal with potential conflicts and benefits. Some attorneys have advice, too.
The growth-equity and late-stage heavy portfolio of the $116bn LP cratered at the beginning of the pandemic, but it largely made up lost ground and then some by mid-year, with Sequoia Capital's recovery standing out.
Apurva Mehta and Patrick O'Connor built a top-performing emerging manager VC portfolio while they were co-CIOs of a hospital endowment in Texas. Two years ago, they converted those partnerships into an FoF.
Biotech VCs have played a crucial role in developing medicines for the disorder before selling them to big pharma, and they've realized exceptional returns while making a difference in patients' lives.